Editas has a permanent CEO again
It's official: After serving as Editas Medicine's interim CEO and president since January, biotech veteran Cynthia Collins has been appointed to the jobs "permanently," board chair James Mullen said in a statement on Tuesday.
The move comes less than two weeks after Editas began enrolling patients in a clinical trial of its lead drug candidate, which uses CRISPR-Cas9 to treat a form of congenital blindness. As the first trial using CRISPR to edit the DNA of patients inside their body (rather than cells isolated from blood, CRISPR'ed in the lab, and then returned), it's being watched with equal parts hope and fear as a harbinger of whether CRISPR can live up to sky-high expectations.
Collins, who in a statement praised Editas's "limitless potential," was previously the CEO of Human Longevity and Clarient Diagnostics, with turns at Beckman Coulter and Sequoia Pharmaceuticals.
The move comes less than two weeks after Editas began enrolling patients in a clinical trial of its lead drug candidate, which uses CRISPR-Cas9 to treat a form of congenital blindness. As the first trial using CRISPR to edit the DNA of patients inside their body (rather than cells isolated from blood, CRISPR'ed in the lab, and then returned), it's being watched with equal parts hope and fear as a harbinger of whether CRISPR can live up to sky-high expectations.
Collins, who in a statement praised Editas's "limitless potential," was previously the CEO of Human Longevity and Clarient Diagnostics, with turns at Beckman Coulter and Sequoia Pharmaceuticals.
No hay comentarios:
Publicar un comentario